July 2021 - The world we live in and the technology we use are rapidly evolving. But, when it comes to drug delivery methods, the 160-year old technology behind the needle and syringe has yet to catch wind of any radical transformation.
There are self-driving cars, 5G smartphones, and now planes that travel from New York to London in 3.5 hours. The world we live in and the technology we use are rapidly evolving. But, when it comes to drug delivery methods, the 160-year old technology behind the needle and syringe has yet to catch wind of any radical transformation. With cutting-edge technology from MIT, Portal Instruments aims to transform how injections are given while improving the experience for patients on life-changing therapies.
Portal Instruments is developing a drug delivery platform that is needle-free, fast, and connected to redefine the patient experience. For patients who dread taking shots, Portal’s needle-free injector could offer a new alternative. Drug administration is over in half a second, making Portal’s needle-free injector 30 times faster than the conventional needle and syringe.¹ Portal’s device can be connected to customizable disease management apps to enable patients to automatically track their injections and manage their chronic condition.
With cutting-edge technology, Portal is able to push the boundaries of how injections are delivered today. Patients deserve more advanced drug delivery methods and at Portal, we envision a better patient experience and a needle-free future.
¹ Portal Data on file.
Portal Instruments, a leader in patient-centric drug delivery innovation, is pleased to announce the publication of a collaborative study in the journal Bioengineering & Translational Medicine, highlighting the viability of its next-generation, needle-free injector (NFI) fo
November 2024, Cambridge, MA – Seasoned drug delivery executive, Steven Kaufman, to join Portal Instruments as their Chief Commercial Officer. Prior to joining Portal Instruments in November 2024, Steven held executive positions at Stevanato Group, Bespak and SHL Medical.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
Please fill out the details below and we will get back to you shortly.